ABVC
ABVC BioPharma, Inc.NASDAQHealthcare$1.39+27.52%ClosedMarket Cap: $20.1M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
2.91
P/S
0.00
EV/EBITDA
-3.84
DCF Value
$-3.55
FCF Yield
1.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-88.9%
ROA
-37.5%
ROIC
-42.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $-796.0K | 26.9% | $-3.0M | $-3.6M | $0.13 | — |
| FY 2025 | $796.0K | 100.0% | $-7.2M | $-7.9M | $-0.39 | — |
| Q3 2025 | $796.0K | 100.0% | $-1.2M | $-1.2M | $-0.05 | — |
| Q2 2025 | $0.00 | NaN% | $-2.3M | $-2.3M | $-0.13 | — |
| Q1 2025 | $0.00 | NaN% | $-693.0K | $-842.1K | $-0.06 | — |
| Q4 2024 | $2.0K | 100.0% | $-334.2K | $229.3K | $0.02 | — |
| FY 2024 | $509.6K | 99.9% | $-4.7M | $-4.9M | $-0.42 | — |
| Q3 2024 | $389.3K | 99.9% | $49.9K | $-186.6K | $-0.02 | — |
| Q2 2024 | $117.1K | 99.8% | $-860.1K | $-942.3K | $-0.08 | — |
| Q1 2024 | $1.2K | 77.0% | $-2.8M | $-2.8M | $-0.29 | — |
| Q4 2023 | $2.2K | -6329.8% | $-2.0M | $-3.1M | $-0.44 | — |
| FY 2023 | $152.4K | -98.1% | $-6.8M | $-7.8M | $-1.80 | — |